Recursion Pharmaceuticals Target of Unusually High Options Trading (NASDAQ:RXRX)

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) saw unusually large options trading activity on Wednesday. Stock investors acquired 7,667 call options on the company. This is an increase of 58% compared to the average daily volume of 4,843 call options.

Insider Transactions at Recursion Pharmaceuticals

In other news, Director Blake Borgeson sold 11,447 shares of the business’s stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $6.27, for a total transaction of $71,772.69. Following the sale, the director now owns 7,121,322 shares in the company, valued at $44,650,688.94. The trade was a 0.16 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Christopher Gibson sold 20,000 shares of the company’s stock in a transaction that occurred on Wednesday, September 4th. The shares were sold at an average price of $6.04, for a total transaction of $120,800.00. Following the completion of the transaction, the chief executive officer now owns 762,656 shares in the company, valued at approximately $4,606,442.24. This represents a 2.56 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 171,682 shares of company stock valued at $1,133,471. Company insiders own 15.75% of the company’s stock.

Institutional Investors Weigh In On Recursion Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of the company. Allspring Global Investments Holdings LLC bought a new stake in Recursion Pharmaceuticals in the third quarter valued at approximately $25,000. Farther Finance Advisors LLC boosted its holdings in Recursion Pharmaceuticals by 176.9% in the third quarter. Farther Finance Advisors LLC now owns 6,404 shares of the company’s stock valued at $42,000 after acquiring an additional 4,091 shares during the last quarter. GAMMA Investing LLC boosted its holdings in shares of Recursion Pharmaceuticals by 1,588.4% during the 2nd quarter. GAMMA Investing LLC now owns 6,416 shares of the company’s stock worth $48,000 after buying an additional 6,036 shares in the last quarter. KBC Group NV boosted its holdings in shares of Recursion Pharmaceuticals by 79.9% during the 3rd quarter. KBC Group NV now owns 7,602 shares of the company’s stock worth $50,000 after buying an additional 3,377 shares in the last quarter. Finally, Amalgamated Bank boosted its holdings in shares of Recursion Pharmaceuticals by 52.4% during the 2nd quarter. Amalgamated Bank now owns 7,152 shares of the company’s stock worth $54,000 after buying an additional 2,459 shares in the last quarter. Institutional investors own 89.06% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on RXRX shares. Jefferies Financial Group dropped their price objective on shares of Recursion Pharmaceuticals from $8.00 to $6.00 and set a “hold” rating for the company in a research note on Tuesday, September 3rd. Leerink Partners reduced their price objective on shares of Recursion Pharmaceuticals from $9.00 to $8.00 and set a “market perform” rating on the stock in a research note on Tuesday, September 3rd. Finally, Needham & Company LLC restated a “buy” rating and set a $11.00 target price on shares of Recursion Pharmaceuticals in a report on Wednesday. Three investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $9.25.

Recursion Pharmaceuticals Trading Down 3.7 %

RXRX stock opened at $6.04 on Thursday. The company has a debt-to-equity ratio of 0.04, a current ratio of 4.35 and a quick ratio of 4.35. The company has a fifty day moving average price of $6.65 and a two-hundred day moving average price of $7.54. Recursion Pharmaceuticals has a one year low of $5.70 and a one year high of $15.74. The stock has a market cap of $1.73 billion, a price-to-earnings ratio of -3.95 and a beta of 0.81.

Recursion Pharmaceuticals (NASDAQ:RXRX) last announced its earnings results on Wednesday, November 6th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.01). The business had revenue of $26.08 million during the quarter, compared to the consensus estimate of $12.62 million. Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%. The company’s revenue was up 147.6% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.43) EPS. Equities analysts anticipate that Recursion Pharmaceuticals will post -1.56 EPS for the current year.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.